近五年累计净亏损超30亿元 智翔金泰离盈利还有多远？

Core Viewpoint - The company Zhixiang Jintai-U (688443.SH) reported significant revenue growth for 2025, driven by the expansion of its first commercial product, but it still faces substantial net losses, indicating a distance from profitability [1][2]. Group 1: Financial Performance - In 2025, Zhixiang Jintai achieved total revenue of approximately 231 million yuan, representing a year-on-year increase of 666.65% compared to 2024 [1]. - The company reported a net loss attributable to shareholders of 536 million yuan, which is a reduction of 32.74% year-on-year [1]. - The net loss excluding non-recurring items was 579 million yuan, with a year-on-year decrease of 27.99% [1]. - As of the end of 2025, the total assets of the company were 2.993 billion yuan, a decrease of 4.87% from the previous year [1]. - The equity attributable to shareholders was 1.584 billion yuan, down 25.49% year-on-year [1]. Group 2: Product Development and Market Expansion - The revenue growth was primarily due to the market expansion of the first commercial product, the monoclonal antibody injection, Saliqi (金立希®), which saw steady sales growth [2]. - The company also benefited from significant licensing income related to the GR1803 injection, positively impacting net profit [2]. - Saliqi is the first fully human anti-IL-17A monoclonal antibody approved in China, with approvals for psoriasis and ankylosing spondylitis in August 2024 and January 2025, respectively [2]. - The company announced that the GR1802 injection for adult seasonal allergic rhinitis met its primary endpoint in Phase III clinical trials, and a new drug application has been submitted and accepted [2]. - Multiple indications for GR1802 are in clinical trials, including chronic sinusitis with nasal polyps and chronic spontaneous urticaria [2][3].